Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Central versus Peripheral Tumor Location Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell Lung Cancer

Central versus Peripheral Tumor Location Influence on Survival, Local Control, and Toxicity... ORIGINAL ARTICLE Central versus Peripheral Tumor Location Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell Lung Cancer Henry S. Park, MD, MPH, Eileen M. Harder, BS, Brandon R. Mancini, MD, and Roy H. Decker, MD, PhD Key Words: Stereotactic body radiation therapy, Central, Non– Introduction: Stereotactic body radiotherapy (SBRT) has been small-cell lung cancer, toxicity. increasingly utilized for medically inoperable early stage non–small- cell lung cancer. However, a lower biological equivalent dose (BED) (J Thorac Oncol. 2015;10: 832–837) is often used for central tumors given toxicity concerns, potentially leading to decreased local control (LC). We compared survival, LC, and toxicity outcomes for SBRT patients with centrally versus tereotactic body radiotherapy (SBRT) has been increas- peripherally located tumors. Singly utilized in the management of medically inoper- Methods: We included patients with primary cT1-2N0M0 non– able early stage non–small-cell lung cancer (NSCLC). For small-cell lung cancer treated with SBRT at our institution from peripheral tumors, the Radiation Therapy Oncology Group September 2007 to August 2013 with follow-up through August (RTOG) 0236 phase II trial demonstrated a 3-year primary 2014. Central tumor location was defined as within 2 cm of the proxi- tumor control of 97.6% and 3-year lobar control http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Central versus Peripheral Tumor Location Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell Lung Cancer

Decker, Roy H.
Journal of Thoracic Oncology , Volume 10 (5) – May 1, 2015
Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/central-versus-peripheral-tumor-location-influence-on-survival-local-SWVJQStGWt

References (17)

Copyright
Copyright © 2015 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000484
pmid
25634007
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Central versus Peripheral Tumor Location Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell Lung Cancer Henry S. Park, MD, MPH, Eileen M. Harder, BS, Brandon R. Mancini, MD, and Roy H. Decker, MD, PhD Key Words: Stereotactic body radiation therapy, Central, Non– Introduction: Stereotactic body radiotherapy (SBRT) has been small-cell lung cancer, toxicity. increasingly utilized for medically inoperable early stage non–small- cell lung cancer. However, a lower biological equivalent dose (BED) (J Thorac Oncol. 2015;10: 832–837) is often used for central tumors given toxicity concerns, potentially leading to decreased local control (LC). We compared survival, LC, and toxicity outcomes for SBRT patients with centrally versus tereotactic body radiotherapy (SBRT) has been increas- peripherally located tumors. Singly utilized in the management of medically inoper- Methods: We included patients with primary cT1-2N0M0 non– able early stage non–small-cell lung cancer (NSCLC). For small-cell lung cancer treated with SBRT at our institution from peripheral tumors, the Radiation Therapy Oncology Group September 2007 to August 2013 with follow-up through August (RTOG) 0236 phase II trial demonstrated a 3-year primary 2014. Central tumor location was defined as within 2 cm of the proxi- tumor control of 97.6% and 3-year lobar control

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: May 1, 2015

There are no references for this article.